GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » enVVeno Medical Corp (NAS:NVNO) » Definitions » Gross Profit

enVVeno Medical (enVVeno Medical) Gross Profit : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is enVVeno Medical Gross Profit?

enVVeno Medical's gross profit for the three months ended in Mar. 2024 was $0.00 Mil. enVVeno Medical's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. enVVeno Medical's gross profit for the three months ended in Mar. 2024 was $0.00 Mil. enVVeno Medical's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, enVVeno Medical's Gross Margin % for the quarter that ended in Mar. 2024 was N/A%.

enVVeno Medical had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage

During the past 9 years, the highest Gross Margin % of enVVeno Medical was 0.47%. The lowest was -3.05%. And the median was -1.29%.


enVVeno Medical Gross Profit Historical Data

The historical data trend for enVVeno Medical's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

enVVeno Medical Gross Profit Chart

enVVeno Medical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only 0.03 - - - -

enVVeno Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of enVVeno Medical's Gross Profit

For the Medical Devices subindustry, enVVeno Medical's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


enVVeno Medical's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, enVVeno Medical's Gross Profit distribution charts can be found below:

* The bar in red indicates where enVVeno Medical's Gross Profit falls into.



enVVeno Medical Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

enVVeno Medical's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

enVVeno Medical's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

enVVeno Medical's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


enVVeno Medical  (NAS:NVNO) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

enVVeno Medical had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage


enVVeno Medical Gross Profit Related Terms

Thank you for viewing the detailed overview of enVVeno Medical's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


enVVeno Medical (enVVeno Medical) Business Description

Traded in Other Exchanges
Address
70 Doppler, Irvine, CA, USA, 92618
enVVeno Medical Corp is a medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
Executives
Hamed Alavi officer: Chief Technology Officer ENVVENO MEDICAL CORPORATION, 70 DOPPLER, IRVINE CA 92618
Francis Duhay director HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Sanjay Shrivastava director HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert Andrew Berman director, officer: CEO C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Matthew Jenusaitis director 2 GOODYEAR, IRVINE CA 92618
Robert Gray director 70 DOPPLER, IRVINE CA 92618
Marc H. Glickman officer: See Remarks 70 DOPPLER, IRVINE CA 92618
Biodyne Holding, S.a. 10 percent owner 13 RUE DE LA GARE, MORGES V8 1110
Craig Glynn officer: Chief Financial Officer 70 DOPPLER, IRVINE CA 92618
Marcus W. Robins director C/O HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert A Rankin officer: Chief Financial Officer 9200 SUNSET BLVD., SUITE 425, WEST HOLLYWOOD CA 90069
Browston Trading Ltd 10 percent owner P.O. BOX 20533, NICOSIA G4 1660
Robert W. Doyle director 70 DOPPLER, IRVINE CA 92618
Robert A. Anderson director 70 DOPPLER, IRVINE CA 92618
Susan Montoya officer: See Remarks 70 DOPPLER, IRVINE CA 92618